Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Research Report 2023

Report ID: 1971815 | Published Date: Jan 2025 | No. of Page: 116 | Base Year: 2024 | Rating: 4.5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 Prevention
        1.2.3 Physiotherapy
        1.2.4 Immunity Therapy
    1.3 Market by Application
        1.3.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Hospitals
        1.3.3 Ambulatory Surgical Center
        1.3.4 Diagnostic Centers
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Perspective (2017-2028)
    2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Growth Trends by Region
        2.2.1 Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Region (2017-2022)
        2.2.3 Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Region (2023-2028)
    2.3 Ventilator Associated Pneumonia (VAP) Therapeutics Market Dynamics
        2.3.1 Ventilator Associated Pneumonia (VAP) Therapeutics Industry Trends
        2.3.2 Ventilator Associated Pneumonia (VAP) Therapeutics Market Drivers
        2.3.3 Ventilator Associated Pneumonia (VAP) Therapeutics Market Challenges
        2.3.4 Ventilator Associated Pneumonia (VAP) Therapeutics Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Revenue
        3.1.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Revenue (2017-2022)
        3.1.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Players (2017-2022)
    3.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue
    3.4 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio
        3.4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in 2021
    3.5 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players Head office and Area Served
    3.6 Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Product Solution and Service
    3.7 Date of Enter into Ventilator Associated Pneumonia (VAP) Therapeutics Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Type
    4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Type (2017-2022)
    4.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Type (2023-2028)
5 Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Application
    5.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Application (2017-2022)
    5.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
    6.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022)
    6.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
    7.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022)
    7.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
    8.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022)
    8.3 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
    9.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022)
    9.3 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2017-2028)
    10.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022)
    10.3 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 Achaogen
        11.1.1 Achaogen Company Detail
        11.1.2 Achaogen Business Overview
        11.1.3 Achaogen Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.1.4 Achaogen Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.1.5 Achaogen Recent Development
    11.2 Adenium Biotech
        11.2.1 Adenium Biotech Company Detail
        11.2.2 Adenium Biotech Business Overview
        11.2.3 Adenium Biotech Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.2.4 Adenium Biotech Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.2.5 Adenium Biotech Recent Development
    11.3 Aridis Pharmaceuticals
        11.3.1 Aridis Pharmaceuticals Company Detail
        11.3.2 Aridis Pharmaceuticals Business Overview
        11.3.3 Aridis Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.3.4 Aridis Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.3.5 Aridis Pharmaceuticals Recent Development
    11.4 AstraZeneca
        11.4.1 AstraZeneca Company Detail
        11.4.2 AstraZeneca Business Overview
        11.4.3 AstraZeneca Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.4.4 AstraZeneca Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.4.5 AstraZeneca Recent Development
    11.5 Bayer
        11.5.1 Bayer Company Detail
        11.5.2 Bayer Business Overview
        11.5.3 Bayer Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.5.4 Bayer Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.5.5 Bayer Recent Development
    11.6 Cardeas Pharma
        11.6.1 Cardeas Pharma Company Detail
        11.6.2 Cardeas Pharma Business Overview
        11.6.3 Cardeas Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.6.4 Cardeas Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.6.5 Cardeas Pharma Recent Development
    11.7 Destiny Pharma
        11.7.1 Destiny Pharma Company Detail
        11.7.2 Destiny Pharma Business Overview
        11.7.3 Destiny Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.7.4 Destiny Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.7.5 Destiny Pharma Recent Development
    11.8 Dong-A Socio Holdings
        11.8.1 Dong-A Socio Holdings Company Detail
        11.8.2 Dong-A Socio Holdings Business Overview
        11.8.3 Dong-A Socio Holdings Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.8.4 Dong-A Socio Holdings Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.8.5 Dong-A Socio Holdings Recent Development
    11.9 Lakewood-Amedex
        11.9.1 Lakewood-Amedex Company Detail
        11.9.2 Lakewood-Amedex Business Overview
        11.9.3 Lakewood-Amedex Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.9.4 Lakewood-Amedex Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.9.5 Lakewood-Amedex Recent Development
    11.10 MedImmune
        11.10.1 MedImmune Company Detail
        11.10.2 MedImmune Business Overview
        11.10.3 MedImmune Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.10.4 MedImmune Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.10.5 MedImmune Recent Development
    11.11 Meiji Seika Pharma
        11.11.1 Meiji Seika Pharma Company Detail
        11.11.2 Meiji Seika Pharma Business Overview
        11.11.3 Meiji Seika Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.11.4 Meiji Seika Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.11.5 Meiji Seika Pharma Recent Development
    11.12 Merck & Co
        11.12.1 Merck & Co Company Detail
        11.12.2 Merck & Co Business Overview
        11.12.3 Merck & Co Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.12.4 Merck & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.12.5 Merck & Co Recent Development
    11.13 Motif Bio
        11.13.1 Motif Bio Company Detail
        11.13.2 Motif Bio Business Overview
        11.13.3 Motif Bio Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.13.4 Motif Bio Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.13.5 Motif Bio Recent Development
    11.14 Nabriva Therapeutics
        11.14.1 Nabriva Therapeutics Company Detail
        11.14.2 Nabriva Therapeutics Business Overview
        11.14.3 Nabriva Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.14.4 Nabriva Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.14.5 Nabriva Therapeutics Recent Development
    11.15 Polyphor
        11.15.1 Polyphor Company Detail
        11.15.2 Polyphor Business Overview
        11.15.3 Polyphor Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.15.4 Polyphor Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.15.5 Polyphor Recent Development
    11.16 Shionogi & Co
        11.16.1 Shionogi & Co Company Detail
        11.16.2 Shionogi & Co Business Overview
        11.16.3 Shionogi & Co Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.16.4 Shionogi & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.16.5 Shionogi & Co Recent Development
    11.17 Tetraphase Pharmaceuticals
        11.17.1 Tetraphase Pharmaceuticals Company Detail
        11.17.2 Tetraphase Pharmaceuticals Business Overview
        11.17.3 Tetraphase Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.17.4 Tetraphase Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.17.5 Tetraphase Pharmaceuticals Recent Development
    11.18 The Medicines Company
        11.18.1 The Medicines Company Company Detail
        11.18.2 The Medicines Company Business Overview
        11.18.3 The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.18.4 The Medicines Company Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.18.5 The Medicines Company Recent Development
    11.19 Theravance Biopharma
        11.19.1 Theravance Biopharma Company Detail
        11.19.2 Theravance Biopharma Business Overview
        11.19.3 Theravance Biopharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.19.4 Theravance Biopharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.19.5 Theravance Biopharma Recent Development
    11.20 Wockhardt
        11.20.1 Wockhardt Company Detail
        11.20.2 Wockhardt Business Overview
        11.20.3 Wockhardt Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.20.4 Wockhardt Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.20.5 Wockhardt Recent Development
    11.21 Zavante Therapeutics
        11.21.1 Zavante Therapeutics Company Detail
        11.21.2 Zavante Therapeutics Business Overview
        11.21.3 Zavante Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
        11.21.4 Zavante Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
        11.21.5 Zavante Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of Prevention
    Table 3. Key Players of Physiotherapy
    Table 4. Key Players of Immunity Therapy
    Table 5. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 6. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 7. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 8. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Region (2017-2022)
    Table 9. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 10. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Region (2023-2028)
    Table 11. Ventilator Associated Pneumonia (VAP) Therapeutics Market Trends
    Table 12. Ventilator Associated Pneumonia (VAP) Therapeutics Market Drivers
    Table 13. Ventilator Associated Pneumonia (VAP) Therapeutics Market Challenges
    Table 14. Ventilator Associated Pneumonia (VAP) Therapeutics Market Restraints
    Table 15. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue by Players (2017-2022) & (US$ Million)
    Table 16. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Players (2017-2022)
    Table 17. Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics as of 2021)
    Table 18. Ranking of Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Companies by Revenue (US$ Million) in 2021
    Table 19. Global 5 Largest Players Market Share by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (CR5 and HHI) & (2017-2022)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Product Solution and Service
    Table 22. Date of Enter into Ventilator Associated Pneumonia (VAP) Therapeutics Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 25. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2017-2022)
    Table 26. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 27. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2023-2028)
    Table 28. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 29. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Application (2017-2022)
    Table 30. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 31. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Application (2023-2028)
    Table 32. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 33. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 34. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 35. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 36. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 37. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2023-2028) & (US$ Million)
    Table 38. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 39. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 40. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 41. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 42. Achaogen Company Detail
    Table 43. Achaogen Business Overview
    Table 44. Achaogen Ventilator Associated Pneumonia (VAP) Therapeutics Product
    Table 45. Achaogen Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 46. Achaogen Recent Development
    Table 47. Adenium Biotech Company Detail
    Table 48. Adenium Biotech Business Overview
    Table 49. Adenium Biotech Ventilator Associated Pneumonia (VAP) Therapeutics Product
    Table 50. Adenium Biotech Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 51. Adenium Biotech Recent Development
    Table 52. Aridis Pharmaceuticals Company Detail
    Table 53. Aridis Pharmaceuticals Business Overview
    Table 54. Aridis Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Product
    Table 55. Aridis Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 56. Aridis Pharmaceuticals Recent Development
    Table 57. AstraZeneca Company Detail
    Table 58. AstraZeneca Business Overview
    Table 59. AstraZeneca Ventilator Associated Pneumonia (VAP) Therapeutics Product
    Table 60. AstraZeneca Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 61. AstraZeneca Recent Development
    Table 62. Bayer Company Detail
    Table 63. Bayer Business Overview
    Table 64. Bayer Ventilator Associated Pneumonia (VAP) Therapeutics Product
    Table 65. Bayer Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 66. Bayer Recent Development
    Table 67. Cardeas Pharma Company Detail
    Table 68. Cardeas Pharma Business Overview
    Table 69. Cardeas Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Product
    Table 70. Cardeas Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 71. Cardeas Pharma Recent Development
    Table 72. Destiny Pharma Company Detail
    Table 73. Destiny Pharma Business Overview
    Table 74. Destiny Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Product
    Table 75. Destiny Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 76. Destiny Pharma Recent Development
    Table 77. Dong-A Socio Holdings Company Detail
    Table 78. Dong-A Socio Holdings Business Overview
    Table 79. Dong-A Socio Holdings Ventilator Associated Pneumonia (VAP) Therapeutics Product
    Table 80. Dong-A Socio Holdings Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 81. Dong-A Socio Holdings Recent Development
    Table 82. Lakewood-Amedex Company Detail
    Table 83. Lakewood-Amedex Business Overview
    Table 84. Lakewood-Amedex Ventilator Associated Pneumonia (VAP) Therapeutics Product
    Table 85. Lakewood-Amedex Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 86. Lakewood-Amedex Recent Development
    Table 87. MedImmune Company Detail
    Table 88. MedImmune Business Overview
    Table 89. MedImmune Ventilator Associated Pneumonia (VAP) Therapeutics Product
    Table 90. MedImmune Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 91. MedImmune Recent Development
    Table 92. Meiji Seika Pharma Company Detail
    Table 93. Meiji Seika Pharma Business Overview
    Table 94. Meiji Seika Pharma Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
    Table 95. Meiji Seika Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 96. Meiji Seika Pharma Recent Development
    Table 97. Merck & Co Company Detail
    Table 98. Merck & Co Business Overview
    Table 99. Merck & Co Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
    Table 100. Merck & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 101. Merck & Co Recent Development
    Table 102. Motif Bio Company Detail
    Table 103. Motif Bio Business Overview
    Table 104. Motif Bio Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
    Table 105. Motif Bio Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 106. Motif Bio Recent Development
    Table 107. Nabriva Therapeutics Company Detail
    Table 108. Nabriva Therapeutics Business Overview
    Table 109. Nabriva Therapeutics Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
    Table 110. Nabriva Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 111. Nabriva Therapeutics Recent Development
    Table 112. Polyphor Company Detail
    Table 113. Polyphor Business Overview
    Table 114. Polyphor Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
    Table 115. Polyphor Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 116. Polyphor Recent Development
    Table 117. Shionogi & Co Company Detail
    Table 118. Shionogi & Co Business Overview
    Table 119. Shionogi & Co Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
    Table 120. Shionogi & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 121. Shionogi & Co Recent Development
    Table 122. Tetraphase Pharmaceuticals Company Detail
    Table 123. Tetraphase Pharmaceuticals Business Overview
    Table 124. Tetraphase Pharmaceuticals Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
    Table 125. Tetraphase Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 126. Tetraphase Pharmaceuticals Recent Development
    Table 127. The Medicines Company Company Detail
    Table 128. The Medicines Company Business Overview
    Table 129. The Medicines Company Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
    Table 130. The Medicines Company Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 131. The Medicines Company Recent Development
    Table 132. Theravance Biopharma Company Detail
    Table 133. Theravance Biopharma Business Overview
    Table 134. Theravance Biopharma Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
    Table 135. Theravance Biopharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 136. Theravance Biopharma Recent Development
    Table 137. Wockhardt Company Detail
    Table 138. Wockhardt Business Overview
    Table 139. Wockhardt Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
    Table 140. Wockhardt Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 141. Wockhardt Recent Development
    Table 142. Zavante Therapeutics Company Detail
    Table 143. Zavante Therapeutics Business Overview
    Table 144. Zavante Therapeutics Ventilator Associated Pneumonia (VAP) TherapeuticsProduct
    Table 145. Zavante Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022) & (US$ Million)
    Table 146. Zavante Therapeutics Recent Development
    Table 147. Research Programs/Design for This Report
    Table 148. Key Data Information from Secondary Sources
    Table 149. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type: 2021 VS 2028
    Figure 2. Prevention Features
    Figure 3. Physiotherapy Features
    Figure 4. Immunity Therapy Features
    Figure 5. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application in 2021 & 2028
    Figure 6. Hospitals Case Studies
    Figure 7. Ambulatory Surgical Center Case Studies
    Figure 8. Diagnostic Centers Case Studies
    Figure 9. Ventilator Associated Pneumonia (VAP) Therapeutics Report Years Considered
    Figure 10. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 11. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Region: 2021 VS 2028
    Figure 13. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Players in 2021
    Figure 14. Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics as of 2021)
    Figure 15. The Top 10 and 5 Players Market Share by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in 2021
    Figure 16. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 17. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2017-2028)
    Figure 18. United States Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 19. Canada Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2017-2028)
    Figure 22. Germany Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. France Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. U.K. Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. Italy Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Russia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Nordic Countries Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Region (2017-2028)
    Figure 30. China Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. South Korea Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. India Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Australia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2017-2028)
    Figure 38. Mexico Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Brazil Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Country (2017-2028)
    Figure 42. Turkey Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Saudi Arabia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. Achaogen Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 45. Adenium Biotech Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 46. Aridis Pharmaceuticals Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 47. AstraZeneca Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 48. Bayer Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 49. Cardeas Pharma Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 50. Destiny Pharma Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 51. Dong-A Socio Holdings Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 52. Lakewood-Amedex Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 53. MedImmune Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 54. Meiji Seika Pharma Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 55. Merck & Co Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 56. Motif Bio Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 57. Nabriva Therapeutics Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 58. Polyphor Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 59. Shionogi & Co Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 60. Tetraphase Pharmaceuticals Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 61. The Medicines Company Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 62. Theravance Biopharma Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 63. Wockhardt Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 64. Zavante Therapeutics Revenue Growth Rate in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2017-2022)
    Figure 65. Bottom-up and Top-down Approaches for This Report
    Figure 66. Data Triangulation
    Figure 67. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Achaogen
Adenium Biotech
Aridis Pharmaceuticals
AstraZeneca
Bayer
Cardeas Pharma
Destiny Pharma
Dong-A Socio Holdings
Lakewood-Amedex
MedImmune
Meiji Seika Pharma
Merck & Co
Motif Bio
Nabriva Therapeutics
Polyphor
Shionogi & Co
Tetraphase Pharmaceuticals
The Medicines Company
Theravance Biopharma
Wockhardt
Zavante Therapeutics
Frequently Asked Questions
Ventilator Associated Pneumonia (VAP) Therapeutics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Ventilator Associated Pneumonia (VAP) Therapeutics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Ventilator Associated Pneumonia (VAP) Therapeutics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Diabetic Shoes

The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More